相关实验视频

Updated: Jan 9, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

前列腺癌中PARP抑制剂:广泛使用还是患者选择?

Ignacio González-Ginel¹, Alfredo Rodriguez-Antolin², David Olmos³

¹Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain; Institute of Biomedical Research, Hospital Universitario 12 de Octubre, Madrid, Spain.

European urology focus

|December 6, 2025

概括

PARP 抑制剂在转移性割抵抗性前列腺癌 (mCRPC) 中显示出有效性. 虽然已被批准用于欧洲所有mCRPC患者,但对BRCA或其他同类重组修复 (HRR) 基因突变患者的益处最大.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

转移性割抵抗性前列腺癌 (mCRPC) 是前列腺癌的晚期阶段.
PARP 抑制剂 (PARPi) 向DNA修复通路,在特定的癌症类型中显示出有前途.
以前对mCRPC中PARPi的批准仅限于患有BRCA或其他同源复合修复 (HRR) 基因变异的患者.

研究的目的:

审查PARP抑制剂在mCRPC患者中有效性的证据.
评估PARPi在mCRPC的组合治疗中的扩大使用.
确定从PARPi治疗中获益最多的患者子组.

主要方法:

审查现有的临床试验数据和科学文献.
对单独和与雄激素受体通路抑制剂结合使用PARPi的疗效和安全数据的分析.
基于基因变化,特别是HRR基因的患者结局的分层.

主要成果:

PARP 抑制剂在不同患者群体的mCRPC中显示出有效性.
与PARPi和雄激素受体通路抑制剂的联合治疗已被批准用于欧洲所有mCRPC患者.
患有BRCA和其他HRR基因突变的患者始终表现出PARPi治疗的最大临床益处.
在所有评估的患者群体中,PARPi的安全概况是一致的.

结论:

在mCRPC中,PARP抑制剂是一种有价值的治疗选择.
扩大批准扩大了治疗机会,但基因分析仍然对确定最佳候选人至关重要.
进一步的研究可能会根据特定的HRR基因变异来完善PARPi在mCRPC中的作用.

关键词:

这种基因是BRCA基因.同类的重组修复.这是一种PARP抑制剂.前列腺癌是什么意思前列腺癌是什么意思

更多相关视频

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...